Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I thought for sure there was an unseen buyer looking for 250K at the close.....Came close but 100k off.
Watch there be a qtr. MM hiding in a hole, let's see.
I'll give it till 8:00 and that's it.. :)
When will the cancel appear?
Let the horses go....
LOUD N'CLEAR
It (5 min. daily).. looks like a 2 stage rocket ship siting at the end of the launch pad with lift off AH and second stage trust @ .68 and off in space....there, let's all have a good LOL going into orbit.
CAR-T MD Anderson all over the news
Very well North appreciate your comment
Thank you
Not trying to be so technical here!
Reading the first para implies another agent is used first. NO??
Edit...And not mentioned so bavi comes to mind to start the immune system.
That is not the way I understand the first paragraph.
Prostate cancer, notoriously resistant to immunotherapy due to its immunologically cool nature, triggers two pathways to chill an immune attack after one immunotherapy drug fires up the immune system, researchers at The University of Texas MD Anderson Cancer Center report in Nature Medicine.
two pathways to chill an immune attack after one immunotherapy drug fires up the immune system, researchers at The University of Texas MD Anderson Cancer Center report in Nature Medicine.
The first being Bavi
Could BMY still be in the bavi game.
Prostate cancer, notoriously resistant to immunotherapy due to its immunologically cool nature, triggers two pathways to chill an immune attack after one immunotherapy drug fires up the immune system, researchers at The University of Texas MD Anderson Cancer Center report in Nature Medicine.
Based on their findings, the researchers launched a clinical trial for stage IV prostate cancer in March combining two drugs that target separate brakes on the immune system. The checkpoint inhibitors largely failed individually against the disease. Their results also implicate for the first time on a human tumor a third brake called VISTA in potentially inhibiting immune response.
"We've known that prostate cancer is immunologically cold, or quiet, with very little penetration of the tumors or their surrounding microenvironment by immune cells," said study leader Padmanee Sharma, M.D., Ph.D., professor of Genitourinary Medical Oncology and Immunology.
"Our study explored whether we could increase immune cell infiltration by combining the anti-hormonal drug Lupron with two rounds of the checkpoint inhibitor ipilimumab before surgery in patients with locally advanced prostate cancer," Sharma said.
Immune checkpoint inhibitors treat T cells, white blood cells that are the immune system's targeted weapons, freeing them to attack tumors by blocking proteins on the T cells' surface that shut them down. Ipilimumab blocks CTLA4 on T cells, the first known immune checkpoint, unleashing them to attack. "Untreated prostate cancer is largely a desert for T cells," said co-author Jim Allison, Ph.D., chair of Immunology.
Ipilimumab brings T cells in, but activates PD-L1
Immune analysis of the surgically removed tumors showed high levels of penetration of the tumors by activated T cells. "But we didn't see any complete responses among 16 prostate cancer patients, so we suspected other immune-inhibiting mechanisms had come into play," Sharma said.
Genomic and immune analysis of the tumors found increased levels of immune-suppressing PD-L1 and VISTA. T cells and other immune cells found in the tumors also had both proteins elevated.
PD-L1 connects with the immune checkpoint PD1 on T cells, activating PD1 to shut down the T cell. A number of drugs blocking PD1 are approved for advanced melanoma, Hodgkin lymphoma, lung, kidney, bladder and head and neck cancers. PD1 inhibitors don't work where there is no pre-existing T cell penetration of tumors.
"We concluded that driving T cells into the tumors would be step one, but then the next step would be to block PD-L1 and VISTA," Sharma said.
These results underpin the immunotherapy combination clinical trial: ipilimumab to bring T cells into the tumor, and the PD1 inhibitor nivolumab to defeat the PD-L1/PD1 response that follows. The trial, led by Sharma, will enroll 90 patients at nine centers nationally.
Six therapies approved for treating metastatic, castration-resistant prostate cancer extend survival but none provide durable responses. Nivolumab failed to provide any responses in a small clinical trial. While ipilimumab fell short of proving survival benefit in two phase III clinical trials, a small group of patients had long-term responses.
Targeting VISTA
VISTA has been shown to block immune response in mouse models of human cancer. And the team confirmed in lab studies that an antibody to knock down VISTA freed T cells to attack cancer cells.
Related Stories
Colorectal cancer rates appear to be increasing among young adults
Higher vitamin D levels linked to lower cancer risk, study suggests
Combination of high-intensity ultrasound and immunotherapy may be effective in treating cancer
An inhibitor for VISTA is in phase I clinical trial to gauge safety and dose, but Sharma notes the drug could also be combined in prostate cancer clinical trials after the phase I is completed.
The ligand that activates VISTA has not been identified, Allison said. The team's findings represent the first report of VISTA expression on T cells in human tumors.
Unhelpful macrophages
The researchers also found that white blood cells called macrophages - Latin for "big eaters" -- are also affected by ipilimumab treatment. Macrophages engulf and digest microbes, bits of cellular debris, tumor cells and other odds and ends as part of immune response.
They are also bipolar. In their M1 form, they actively assist immune response. In M2, they are in repair mode, helping post-immune recovery. The M2 mode promotes cancer growth and survival.
Sharma, Allison and colleagues found that macrophages after ipilimumab treatment expressed lots of PD-L1 and VISTA and were in M2 mode.
Serial immune monitoring
"This paper highlights the importance of studying immune response longitudinally," Sharma said. "Observing immune response at one point in time doesn't reflect what's going on because the immune system is so dynamic. So baseline sampling in prostate tumors shows minimal immune infiltrate. You can change that with ipilimumab, but what else changes becomes incredibly important.
"Understanding these changes using post-treatment or on-treatment biopsies is important to develop rational combination strategies for these immune-modulating drugs," she said.
The presurgical clinical trials, also called window of opportunity trials, allow researchers to learn a lot from a small number of patients to guide the design of larger trials, Sharma said.
Immune monitoring of serial biopsies taken before, during and after treatment is a central aspect of MD Anderson's Immunotherapy Platform, which is co-led by Sharma and Allison and provides immune monitoring for 100 clinical trials. The platform is part of MD Anderson's Moon Shots Programâ„¢ to accelerate development of new treatment, prevention and early detection based on scientific advances.
Patient response
In the Lupron-ipilimumab trial, 17 patients participated in the trial, 16 completed treatment and surgery and one died of a cardiac complication before surgery. Six patients had their cancer progress and 10 were without evidence of progression for at least 3.5 years. All 16 remained alive 3.5 years after surgery.
All 17 experienced an immune-related adverse event, with eight experiencing the most serious grade 3 or 4 side effects, including inflammation of the colon, pancreas or pituitary gland and elevated transaminase enzymes in the liver. All were treated with corticosteroids and other immune-suppressive drugs.
The ipilimumab-nivolumab combination is in use in clinical trials for other cancers, most prominently for metastatic melanoma. In a 937-patient randomized trial, the combination provided an overall response rate of 57.7 percent, surpassing either drug alone in response rate and progression-free survival. And 55 percent of patients on the combination experienced a grade 3 or 4 adverse event related to treatment. The prostate combination trial has protocols for recognizing and treating immune-related adverse events.
Source:
http://www.news-medical.net/news/20170329/Study-explores-new-immunotherapy-combinations-to-treat-prostate-cancer.aspx?hl=1&noRedirect=1
Is the race on to close at the HOD @ EOD
Hey, you are most welcome, any time I can help..
Just hate to see you wear your fingers to the bone...Cuz all your gonna get is boney fingers.
I really don't think there will be any more available below .69 at this point agarn.
A whole lot of strange activity in the AH last evening, including that 1 share cancelled trade. Just finding this odd there.
The air so crisp this fine Sat. morn. nothing but fine thoughts of our progressive science being acknowledged and consumed by the masses.
Agree.....Next resistance .76
Good post.
Thomas I feel Dr. Soon was speaking in direct relationship to the posted comments on the AstraZeneca's site.
"Working with external partners who specialise in developing these diagnostics is critical to our continued success in this area."
Joe Biden in the news: Dr. Patrick Soon-Shiong
http://money.cnn.com/2017/03/12/technology/sxsw-joe-biden-cancer/
http://www.twcnews.com/tx/austin/sxsw/2017/03/12/former-vice-president-joe-biden-to-speak-at-sxsw-today-on-cancer-initiative-.html
http://www.usatoday.com/story/tech/news/2017/03/12/joe-biden-cancer-sxsw/99095456/
Well as business goes..
Maybe the g/f has can see an opportunity for a threesome down the road and leverages the moment to her satisfaction. Hmmm who said they had one less rib. Hey working on 1 less hr. sleep here.
Isn't the poison pill really just about dilution?
While I have the weekend perhaps it is time to brush up on this thread. Might shorten the weekend. Thanks to ImaPseudonym/Loof/CP and mony more.
Thanks for the reply TOG
Edit/ADD: And BIG bro
A couple of questions this morning is anyone can help....
1. Do ATM share trade in the pre/after market? Or is it just retail and or MM's moving about?
2. What potential news could possibly be released at EOD?
I do like long walks on the beach, but serious reply's please.
Edit/add: If the PP goes into effect what is the price?
TIA
But before I go to bed and understand your meaning (so I can sleep)
Why is this not possible??
I may be a tad more generous then that IF.
Why first off, he'd get 4 hash marks and with 2 years to go
at least E-7 w/18 yrs in grade. And easy out program to boot!
So, I guess that puts that one at lifer status and all the bennies.
JMO, Geo..
Is it possible, a decision is made, and rif/raf (weak hands) needs to be cleared out. How do you accomplish this.
A. A RS is done in accordance to plan.
B. A strong PR is released at a strategic time leaving those on the wish list in the dust and those on verge of selling, selling! Meaning yes, above five dollars.
Accomplishing both... Locking out new undeserving and too late investors and..........those happy to sell at the five plus ps.
Sound reasonable, possible or insane..Big boy pants on bloused to the ankle. Give it to me.
Oh lookie, that may just dream weaver us into the HOD by EOD.
I think we are going to be alright here! 2.3 mil. at like 1:30
down a cent. So we base a few days. I'll take it.
Is it possible the ones doing battle here don't want to bring attention to themselves? Best to use the BB guns in the night and strike in the eyes. Then proclaim victory in the daylight when the battle is won. But then again how does the war end.
I'm impressed and it's encouraging to see someone supporting this sp.
Almost as saying...Hey I paid my dues here, back off I'm not done yet. Maybe Ronin?!
EOD as we all know by now
Will be the EOD. Ummm, if your asking me I'll defer until after lunch I'm not sure if crow or duck is on the menu. But we for sure will know after it is eaten. How we digest it will be known in the a.m. :)
Why yes....forming
A forming W means we about to wook it up..
Wook it up in wiki or winfestopedia. ha he
ADD....What is this hammer at 11:33 all about? Make the call already.
Some feedback
Another 13D filling yes quite possible, as more II get involved.
However.......
Who was that nice guy that would fly by every once in a while and show us a shot of the chart that had a nice bowl in it about to form a handle.
Gee, can't remember that dude, but would like to thank him. LOL
http://finviz.com/quote.ashx?t=PPHM&ty=c&ta=1&p=d
Good point nem.....
We have all weekend to find them.
Well geez that kinda takes me by surprise coming from where I sit
Is it my math!
After Hours Volume: After Hours High: After Hours Low:
4,555 $ .705
(16:16:08 PM) $ .70
(16:20:39 PM)
Trade Detail
Most Active in the After-Hours
After Hours Time (ET) After Hours Price After Hours Share Volume
16:17:50 $ .70 150
16:16:08 $ .705 High 25
16:16:00 $ .70 80
16:03:40 $ .70 1,000
ADD: OK, the 3,300 just showed up
Thanks Blue I'll take that and I'll take the safely in the green close as well.
LOL, we all feel the same don't we.
Those of us who have done the hard work and held through difficult times are reluctant to say "here, here is PPHM..go for it"
I recently turned down money from a friend as well...They see me spending money like a drunk'n sailor (no disrespect to our sailors out there) and say here.... do this for me at risk of friendship.. NOPE.
Sorry!!
WHOA......
Who is this guy!!
The new and improved WOOKIE